Abbott acknowledged by Science Magazine as a top employer
20 October 2014 | By Abbott
Abbott was named one of the Top 20 Employers by the journal Science...
List view / Grid view
News
Nasdaq welcomes Forward Pharma A/S (Nasdaq: FWP) to The Nasdaq Stock Market
20 October 2014 | By Nasdaq
Nasdaq announced that trading of Forward Pharma A/S (Nasdaq: FWP) commenced on The Nasdaq Stock Market on October 15, 2014....
AstraZeneca strengthens partnership with the University of Cambridge
20 October 2014 | By AstraZeneca
AstraZeneca, together with its global biologics research and development arm, MedImmune, announced that it has entered into four new collaborations with the University of Cambridge, building further on their existing partnership...
METTLER TOLEDO’s XS Balance line delivers performance and ergonomics to safeguard health in the workplace
16 October 2014 | By METTLER TOLEDO
The extended and improved XS balance line incorporates patented weighing technologies to ensure accurate results whilst ergonomic design features provide outstanding comfort to protect user health during daily weighing tasks.
METTLER TOLEDO launch new XPE Balance portfolio designed for performance and ease of compliance
16 October 2014 | By METTLER TOLEDO
The new line of XPE balances focuses on delivering accurate, compliant results and provides users with a high level of process security, suitable for even the strictest regulations...
Santen launches its own Subsidiary in Italy
16 October 2014 | By Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. announced its new wholly owned subsidiary in Italy...
Roche delivers solid sales growth for the first nine months of 2014
16 October 2014 | By Roche
Roche announce Q3 2014 results...
Public-private partnerships vital to advance Ebola treatment pipeline, says GlobalData Analyst
16 October 2014 | By GlobalData
In the battle against Ebola, incentives from governments and healthcare policymakers have been and will continue to be vital for advancing the current treatment pipeline, by mitigating the risk and up-front costs from pharmaceutical companies, says an analyst with research and consulting firm GlobalData...
FDA approves Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States
16 October 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has approved Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis in the United States...
Coulter Partners further strengthens its activities in Europe
15 October 2014 | By Coulter Partners
Coulter Partners, the Global Life sciences search specialist, is delighted to announce the appointment of Tobias (Toby) Ernberg as Executive Vice President...
Promethera Biosciences receives approval in Belgium to enroll patients in the imminent HEP002 Phase IIb/III clinical trial
15 October 2014 | By Promethera Biosciences
HEP002 trial represents the world’s first Phase IIb/III trial with a stem cell-based medicinal product for the treatment of urea cycle disorders patients...
Auspherix and Domainex announce collaboration to develop new drugs to treat antibiotic-resistant bacterial infections
15 October 2014 | By Auspherix & Domainex
Domainex Ltd. and Auspherix Pty Ltd announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate...
Government-backed generics limiting Netherlands’ pharmaceutical market growth, says GlobalData
14 October 2014 | By GlobalData
The Netherlands’ pharmaceutical market value will rise slowly from approximately $6.7 billion in 2014 to $7.2 billion by 2020, with growth restricted by the government’s focus on generic drugs as a cost-containment tool, according to research and consulting firm GlobalData...
Imaxio signs an option for a license agreement with the German Cancer Research Center (DKFZ)
14 October 2014 | By Imaxio
Imaxio’s pro-immunogenic technology will be tested to enhance the efficacy of a candidate vaccine for the human papillomavirus (HPV)...
Pharmalink elects Bengt Julander as chairman
14 October 2014 | By Pharmalink
Pharmalink AB, a specialty pharma company focused on orphan and niche products, has elected Bengt Julander as Chairman of the Board of Directors...
